Nutritional Delivery Systems launches CurcuminPro product line
Nutritional Delivery Systems earlier this week showed off its BioSoluble line of curcumin-based meal-replacement shakes, capsules and candies from its CurcuminPro product line, which uses a tasteless curcumin-protein conjugate called CPro, at January’s ECRM VMS EPPS event.
“ECRM was a great chance to get our CurcuminPro line in front of major players in the retail industry and show them a revolutionary new way to get curcumin into peoples’ diets,” Ron Gourley, CEO Nutritional Delivery Systems said. “We loved discussing the unique CPro conjugate and what it means for the future of health supplements. Our extended research dives in-depth into the benefits of vegetables, fiber, protein, essential amino acids, including BCAAs, antioxidants, vitamins, minerals and many other components of our diverse product line.”
CurcuminPro uses CPro in its curcumin-enhanced products, which include capsules, chewables, powdered drink mixes, bottled drinks, chocolate and jelly bean confections, and even pet food toppers. The active ingredient, CPro, has no taste or odor and is 36 times more soluble than standard curcumin. Curcumin-enriched diets are believed to have all sorts of health benefits, including helping to improve skin, immune system, digestive, skeletal and joint health and liver function.
ECRM’s Vitamin, Weight Management and Sports Nutrition Efficient Program Planning Sessions is a trade show where vitamin, diet and nutrition companies are able to network with major retail buyers in private sessions and show off their products.
Report: J&J pulls out of the race for Pfizer’s consumer business
Johnson & Johnson is officially out of the running for Pfizer’s Consumer business, Reuters reported Thursday.
“While we would normally not comment on market speculation or rumors, in this instance we refute assertions that we are in negotiation for Pfizer’s consumer business,” J&J’s vice president of media relations Ernie Knewitz told Reuters.
That leaves GSK Consumer and RB in the running for the business. Pfizer is accepting bids on its business through Feb. 1 and is hoping to clear at least $20 billion in the sale, Reuters reported.
Drug Store News provided a look at who may or may not be interested in a Pfizer consumer business in Ocotober.
Pfizer fields several leading OTC brands across many of the more significant non-prescription categories. The company boasted almost $600 million in annual sales across U.S. total multi-outlets through its internal analgesic franchise (Advil and Advil PM) for the 52 weeks ended June 11, 2017, according to IRI. The proton pump inhibitor Nexium 24HR generated another $300 million and its vitamin lineup, featuring Centrum, pulled in more than $280 million.
According to Kline Group, based on 2016 sales Bayer holds an 8.2% market share of the overall OTC busines, with Johnson & Johnson following at 7.5% and GlaxoSmithKline Consumer Healthcare at 6.5%. Pfizer stands at No. 4 on that list with a 6.2% market share, followed by Procter & Gamble (4.5%), Sanofi (4.4%), Reckitt Benckiser (4%), Prestige Brands (1.9%), Church & Dwight (1.2%) and Carlyle Group (1%).
The marketshare figures are attributable to Kline & Company’s latest “Nonprescription Drugs USA” study.
For the full Reuters story, click here.
Walgreens Flu Index: Flu incidence snakes north from Texas
Oklahoma, Montana and Iowa topped the list for flu activity gains as flu incidence appears to snake north from Texas, according to this week’s Walgreens Flu Index, the Deerfield, Ill.-based retailer announced Wednesday. Though Texas continued to dominate the map with the number of areas currently experiencing high levels of flu activity.
For the week ended Jan. 20, the top 10 markets presently experiencing flu activity were:
- El Paso, Texas (Las Cruces, N.M.);
- Corpus Christi, Texas;
- Waco-Temple-Bryan, Texas;
- Tyler-Longview (Lufkin & Nacogdoches), Texas;
- Harlingen-Weslaco-Brownsville-McAllen, Texas;
- Dallas-Ft. Worth, Texas;
- Beaumont-Port Arthur, Texas;
- Knoxville, Tenn.;
- Ft. Smith-Fayetteville-Springdale-Rogers, Ark.; and
- Cedar Rapids-Waterloo-Iowa City & Dubuque, Iowa.
The top 10 designated market areas by flu activity gains were:
- Oklahoma City;
- Cedar Rapids-Waterloo-Iowa City & Dubuque, Iowa;
- Lincoln & Hastings-Kearney, Neb.;
- Tulsa, Okla.;
- Chattanooga, Tenn.;
- La Crosse-Eau Claire, Wis.;
- Springfield, Mont.;
- Knoxville, Tenn.;
- Harlingen-Weslaco-Brownsville-McAllen, Texas; and
- Ft. Smith-Fayetteville-Springdale-Rogers, Ark.
The Walgreens Flu Index is a weekly report developed to provide state- and market-specific information regarding flu activity, and ranks those states and markets experiencing the highest incidences of influenza across the country. The Index provides insight by showing which cities or metropolitan areas are experiencing the most incidences of influenza each week based on Index methodology. The data does not measure actual levels or severity of flu activity.
The Index is compiled using weekly retail prescription data for antiviral medications used to treat influenza across Walgreens and Duane Reade locations nationwide, including Walgreens locations in Puerto Rico. The data is analyzed at state and geographic market levels to measure absolute impact and incremental change of antiviral medications on a per store average basis, and does not include markets in which Walgreens has fewer than 10 retail locations.